HONG KONG


ACCUEIL
NOUVELLES
CONCENTRER
OPINION
VIDÉO
LES DONNÉES

AVANCÉE
Actualités > Nation > Contenu






Vendredi 06 mars 2020, 21:14

La Chine optimise le traitement de COVID-19

Par Xinhua



BEIJING - La Chine a étendu et optimisé l'utilisation de médicaments et de thérapies dans le traitement de la nouvelle maladie à coronavirus (COVID-19) pour bloquer la conversion des cas bénins en cas graves et sauver les patients gravement malades.

Le tocilizumab, un médicament contre la polyarthrite rhumatoïde avec le nom de marque commun Actemra, a été inclus dans la dernière version chinoise des directives de diagnostic et de traitement sur COVID-19.


En plus du tocilizumab, le phosphate de chloroquine et certains médicaments traditionnels chinois, ainsi que la thérapie plasmatique convalescente, ont été inclus dans la directive thérapeutique

A LIRE AUSSI: La crise du coronavirus menace de faire taire l'essor touristique du Japon

Zhou Qi, secrétaire général adjoint et académicien de l'Académie chinoise des sciences, a déclaré lors d'une conférence de presse vendredi que le médicament Tocilizumab s'est avéré efficace pour bloquer l'incitation à la tempête inflammatoire.

Dans un essai clinique initial, le tocilizumab a été utilisé dans 20 cas graves de COVID-19. Et les températures corporelles de tous les patients ont chuté en une journée. Dix-neuf des patients sont sortis de l'hôpital dans les deux semaines et un s'est amélioré, selon Zhou.

Actuellement, le médicament fait l'objet d'essais cliniques dans 14 hôpitaux de Wuhan, l'épicentre de l'épidémie, a déclaré Zhou.

Au 5 mars, un total de 272 patients sévères avaient été traités par Tocilizumab.

In addition to Tocilizumab, Chloroquine Phosphate and some traditional Chinese medicines, as well as convalescent plasma therapy, have been included in the treatment guideline. China is also pushing forward the utilization of some advanced technologies such as stem cell and monoclonal antibody technologies in the treatment of severe cases, said Wu Yuanbin, director-general of science and technology for social development of the Ministry of Science and Technology (MOST).

READ MORE: China is not alone in fight against novel coronavirus

The drug Chloroquine Phosphate has been used in treating 285 critically ill COVID-19 patients in a hospital in Wuhan, and no obvious adverse reactions have been found so far, said Sun Yanrong, deputy head of the China National Center for Biotechnology Development under the MOST.

Two clinical trials for Remdesivir are ongoing, and we are looking forward to seeing the results, Sun said.

The combination of traditional Chinese medicines and Western medicines has shown good results in the treatment of COVID-19. Statistics show that 90 percent of the patients in Hubei Province have been treated with traditional Chinese medicines, Sun said.




Share this story


Also Read


Virus origin: Wuhan lab refutes conspiracy theories

Head of Wuhan Institute of Virology said conspiracy theories suggesting that the novel coronavirus originated in his lab had no basis in fact.29 April 2020


Beijing lowers virus response level, to open museums May 1

Under the new response level, people from low-risk regions of China will not need to be quarantined for 14 days at home upon arriving in Beijing.29 April 2020


Xi supports Hubei development in key Party meeting

Xi said arduous efforts have brought a decisive outcome to Hubei and that the nationwide battle against the virus has gained major strategic achievements.29 April 2020


China's top legislature to open annual session on May 22

The 3rd annual session of the 13th National Committee of the Chinese People's Political Consultative Conference was proposed to open on May 21.29 April 2020


Bamboo rat breeders await final decision on industry

Bamboo rat breeders in southern China are keeping their packs alive while they wait for a final decision on the future of the business and details of compensation if the practice is banned.29 April 2020


Stigmatizing China 'distracts global attention from virus fight'

Chinese Ambassador to Britain Liu Xiaoming made the remarks in an opinion piece published on the Financial Times.29 April 2020



Latest News1
Court rejects appeal by activist Edward Leung
2
ILO: Labor market damage from virus could equate to 305m jobs
3
Beijing lowers virus response level, to open museums May 1
4
HK police seize largest amount of crystal meth since 1991
5
Shares gain after encouraging COVID-19 drug data, oil jumps



Photo
Video




A testing time for school start









Panda cub meets the public




A testing time for school start









Panda cub meets the public




A testing time for school start









Panda cub meets the public


1
2
3
4




News

Hong Kong
Nation
Asia
World
Business
Sports
HK Football
Focus

Life & Art
Leaders
Offbeat HK
In-Depth China
Eye on Asia
Quirky
Photo
Video

Urban Tales
Tech China
Biz Leader
Girl City
Drone and Phone
Hong Kong Enquirer
ePaper

Asia Weekly
ASEAN Weekly
Focus Hong Kong
More

Opinion
Data Journalism
Roundtable
Lifestyle Premium
Campus Awards
Global Sources
Through the Dragon's Brush

About Us
Services & Products
Advertise on Site
Contact Us
Subscriptions
Join Us
Accessibility Statement
Privacy Policy

Follow Us




APP


CHINA DAILY HK


Video Shows
CHINA Global Edition


Copyright 1995 - 2020. Tous droits réservés. Le contenu (y compris, mais sans s'y limiter, le texte, la photo, les informations multimédias, etc.) publié sur ce site appartient à China Daily. Sans l'autorisation écrite de China Daily, ce contenu ne doit pas être republié ou utilisé sous quelque forme que ce soit.